NEXT-GENERATION GRASS POLLEN VACCINE

DC4U was recently awarded a 2,7 million euro valued Eurostars project for the development a next-generation allergy vaccine to treat grass-pollen induced allergic rhinitis and asthma. In this project DC4U and its partners UMCG, Fraunhofer Institute, Pharmacelsus, piCHEM and Allergopharma will develop an allergen specific immune therapy based on DC4U’s GlycoDC technology.